Barinthus Biotherapeutics plc.
BRNSBarinthus Biotherapeutics plc (formerly Vaccitech plc) is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
4wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How BRNS's past catalysts played out
MVA-HBV
Chronic Hepatitis B
ChAdOx1-HBV
Hepatitis B
ChAdOx1-HPV
HPV Infection
MVA-NP+M1
Influenza
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MVA-HBV | Phase 2 | Chronic Hepatitis B | - | - |
ChAdOx1-HBV | Phase 2 | Hepatitis B | - | - |
ChAdOx1-HPV | Phase 2 | HPV Infection | - | - |
MVA-NP+M1 | Phase 2 | Influenza | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Barinthus Biotherapeutics plc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Barinthus Biotherapeutics plc.'s (BRNS) pipeline across Phase 2. Its lead program is MVA-HBV (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Barinthus Biotherapeutics plc.'s next FDA catalyst?→
Barinthus Biotherapeutics plc.'s (BRNS) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BRNS biotech catalysts?→
Add BRNS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Barinthus Biotherapeutics plc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.